CA2586074C — Ophthalmic oil-in-water type emulsion with stable positive zeta potential
Assigned to Santen SAS · Expires 2013-07-23 · 13y expired
What this patent protects
An ophthalmic oil-in-water type emulsion, which comprises colloid particles having an oily core surrounded by an interfacial film, said emulsion comprising at least one cationic agent, at least one non ionic surfactant said emulsion having a positive zeta potential and meeting ze…
USPTO Abstract
An ophthalmic oil-in-water type emulsion, which comprises colloid particles having an oily core surrounded by an interfacial film, said emulsion comprising at least one cationic agent, at least one non ionic surfactant said emulsion having a positive zeta potential and meeting zeta potential stability Test A requirements. Process for making said emulsions. Delivery device selected from the group comprising lenses, ocular patch, implant, insert, said device containing an emulsion according to the invention.
Drugs covered by this patent
- Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.